Drug Profile


Alternative Names: PEG nartograstim; Pegylated G-CSF; Pegylated nartograstim; RO 258315

Latest Information Update: 08 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Granulocyte colony-stimulating factors
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stem cell mobilisation

Most Recent Events

  • 08 Nov 2006 Discontinued - Phase-I for Stem cell mobilisation in France (SC)
  • 25 Jan 1999 RO 258315 is now called pegnartograstim (INN)
  • 16 Feb 1998 Data have been added to the adverse events, pharmacokinetics and pharmacodynamics sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top